710
Participants
Start Date
August 13, 2009
Primary Completion Date
January 1, 2025
Study Completion Date
January 1, 2025
Nimotuzumab
Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
Placebo
Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
Flinders Medical Centre, Bedford Park
National Institute of Oncology and Radiobiology, Vedado
Alexandria University School of Medicine, Alexandria
National Cancer Institute, Cairo University, Cairo
Apollo Hospital Bangalore, Bangalore
Narayana Hrudayalaya Hospital (Mazumdar Shaw Cancer Institute), Bangalore
Amrita Institute of Medical Sciences, Kerala
Tata Memorial Centre, Mumbai
Christian Medical College, Tamil Nadu
Regional Cancer Center Trivandrum, India, Trivandrum
Cipto Mangunkusumo General Hospital Indonesia, Jakarta
Pantai Medical Centre, Kuala Lumpur, Kuala Lumpur
Mahkota Medical Center, Malacca
University of Santo Tomas Hospital, Manila
St. Luke's Medical Center, Quezon City
King Fahad Medical City, Riyadh
National Cancer Centre, Singapore
The Oncology Centre, Durban
GVI Oncology, Panorama
National Cancer Center Korea, Gyeonggi-do
INHA University Hospital, Incheon
Samsung Medical Center, Seoul
Severance Hospital, Yonsei University Health System, Seoul
China Medical University Hospital, Taichung
Taipei Med Univ Hosp [TMUH], Taipei
Taipei Veteran General Hospital, Taipei
National Cancer Institute Bangkok (+Chulabhorn for RT), Bangkok
Siriraj Hospital, Bangkok
Chiang Mai Hospital, Chiang Mai
Peter MacCallum Cancer Centre, Melbourne
Collaborators (1)
National Medical Research Council (NMRC), Singapore
OTHER_GOV
Innogene Kalbiotech Pte. Ltd
INDUSTRY
National Cancer Centre, Singapore
OTHER